Sign in Subscribe
Immunotherapy

Liminatus Pharma Secures $30 Million Equity Financing and Strategic Partnership with Capital Trust Group Limited

Strategic Insights

— 1 min read

La Palma, CA-based clinical-stage immuno-oncology company Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) with New Zealand-based Capital Trust Group Limited (CTG) for a $30 million equity financing through an earn-out mechanism. The funds will support the development of Liminatus's advanced immunotherapy assets, while also exploring further strategic cooperation, including potential future digital bond financing programs. According to Chris Kim, Chief Executive Officer of Liminatus Pharma, "We believe that this MOU marks the beginning of a long-term partnership with CTG, and the equity financing would strengthen our financial foundation." Liminatus and CTG aim to finalize and execute the definitive agreements in November 2025.

Key Takeaways:

  • Liminatus Pharma, Inc. has entered into a Memorandum of Understanding with Capital Trust Group Limited for a $30 million equity financing through an earn-out mechanism.
  • The equity financing will support the development of Liminatus's advanced immunotherapy assets.
  • Liminatus and CTG will explore further strategic cooperation, including potential future digital bond financing programs.
  • The companies aim to finalize the definitive agreements in November 2025.
  • Liminatus is a clinical-stage immuno-oncology company pioneering next-generation therapeutics, including its proprietary CD47-blockade antibody IBA101.
  • CTG is a New Zealand-based investment management and digital finance firm managing large-scale institutional and blockchain-enabled financing programs across healthcare, energy, and infrastructure sectors.
  • General Chavalit Yongchaiyudh, the 22nd Prime Minister of Thailand, serves as an honorable advisor to CTG.

Statistics:

  • $30 million equity financing through an earn-out mechanism.
  • Mid-November 2025: Commencement of discussions for additional strategic cooperation, including potential future digital bond financing programs.
  • November 2025: Expected completion and execution of definitive agreements.

Sources:

  • Liminatus Pharma, Inc. press release, October 27, 2025.
  • Capital Trust Group Limited's website: https://www.ctgprime.com/
  • Private Securities Litigation Reform Act of 1995 (forward-looking statements).

Read more